Ophthalmic Pharmacology Practice Questions

Q: Which of the following medications is contraindicated in patients with allergy to sulfonamides?

Brinzolamide. **Explanation:** **Brinzolamide** is a topical Carbonic Anhydrase Inhibitor (CAI) used to reduce intraocular pressure in glaucoma. Chemically, CAIs (including Brinzolamide and Dorzolamide) are **sulfonamide derivatives**. Although administered topically, they undergo systemic absorption. In patients with a known sulfonamide allergy, these drugs can trigger hypersensitivity reactions ranging from mild skin rashes to severe conditions like Stevens-Johnson Syndrome. Therefore, a history of sulfa allergy is a contraindication for their use. **Analysis of Incorrect Options:** * **A. Levobunolol:** This is a non-selective **beta-blocker**. It is contraindicated in patients with asthma, COPD, or bradycardia, but it does not share cross-reactivity with sulfonamides. * **B. Bimatoprost:** This is a **prostaglandin analogue**. Its primary side effects include iris repigmentation, hypertrichosis of lashes, and cystoid macular edema, but it is safe for sulfa-allergic patients. * **C. Brimonidine:** This is a highly selective **alpha-2 adrenergic agonist**. While it frequently causes local follicular conjunctivitis (allergic reaction), it is not a sulfonamide. **High-Yield NEET-PG Pearls:** * **Topical CAIs:** Brinzolamide (suspension, less stinging) and Dorzolamide (solution, more stinging). * **Systemic CAI:** Acetazolamide (Diamox) is also a sulfonamide and carries the same contraindication. * **Mechanism:** CAIs reduce IOP by inhibiting carbonic anhydrase in the ciliary epithelium, thereby decreasing aqueous humor production. * **Cross-Reactivity Rule:** Always screen for sulfa allergy before prescribing CAIs, loop diuretics (Furosemide), or thiazides.

Q: What is the maximum safe dose of lignocaine with adrenaline for local blocks in ophthalmic surgeries?

7 mg/kg. **Explanation:** The maximum safe dose of local anesthetics is a high-yield topic in both Ophthalmology and Anesthesia. The dosage depends primarily on whether a vasoconstrictor (like adrenaline) is added to the solution. **1. Why 7 mg/kg is correct:** Lignocaine (Lidocaine) is an amide-type local anesthetic. When used **with adrenaline** (typically 1:100,000 or 1:200,000 concentration), the adrenaline causes local vasoconstriction. This slows down the systemic absorption of the drug, reduces peak plasma levels, and prolongs the duration of the block. This decreased rate of absorption allows for a higher safe threshold, which is **7 mg/kg**. **2. Analysis of Incorrect Options:** * **3 mg/kg (Option A):** This is significantly below the safe threshold for lignocaine and is not a standard limit for this drug. * **5 mg/kg (Option B):** This is the maximum safe dose for **plain lignocaine** (without adrenaline). Without a vasoconstrictor, the drug is absorbed more rapidly into the systemic circulation, increasing the risk of systemic toxicity (LAST). * **10 mg/kg (Option D):** This dose exceeds the safety limit for lignocaine and carries a high risk of Central Nervous System (CNS) and cardiovascular toxicity. **3. Clinical Pearls for NEET-PG:** * **Maximum Absolute Dose:** Regardless of weight, the total dose of lignocaine with adrenaline should generally not exceed **500 mg** in an adult. * **Ophthalmic Context:** In ophthalmic blocks (Peribulbar/Retrobulbar), a mixture of Lignocaine (2%) and Bupivacaine (0.5%) is often used. Bupivacaine provides a longer duration of action but has a lower safety margin (**2 mg/kg**). * **Hyaluronidase:** Often added to ophthalmic blocks to increase tissue permeability and speed up the onset of the block, though it does not affect the maximum safe dose of the anesthetic itself. * **Early signs of toxicity:** Perioral numbness, metallic taste, and tremors.

Q: Which of the following is used as an adjuvant therapy for fungal corneal ulcer?

Atropine eye drops. **Explanation:** In the management of a fungal corneal ulcer (keratomycosis), **Atropine (1%) eye drops** serve as a vital adjuvant therapy alongside antifungal agents (like Natamycin or Voriconazole). **Why Atropine is the Correct Answer:** Fungal ulcers often trigger a secondary **anterior uveitis** due to the release of inflammatory toxins. Atropine, a potent cycloplegic and mydriatic, provides three key benefits: 1. **Relief of Ciliary Spasm:** It relaxes the ciliary muscle, significantly reducing the deep, aching pain associated with the ulcer. 2. **Prevention of Posterior Synechiae:** By keeping the pupil dilated, it prevents the iris from adhering to the lens capsule. 3. **Reduction of Exudation:** It stabilizes the blood-aqueous barrier, reducing the inflammatory flare in the anterior chamber. **Analysis of Incorrect Options:** * **B. Pilocarpine:** This is a miotic. It would worsen the pain by causing ciliary muscle contraction and increase the risk of forming small-pupil synechiae. * **C. Dexamethasone:** Steroids are generally **contraindicated** in active fungal ulcers as they suppress the local immune response and promote fungal replication/penetration, potentially leading to corneal perforation. * **D. Lidocaine:** While a local anesthetic, it is not used as an adjuvant therapy. Repeated use of topical anesthetics is toxic to the corneal epithelium and can delay healing. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** For filamentous fungi (e.g., *Aspergillus, Fusarium*), the DOC is **Topical Natamycin (5%)**. For *Candida*, **Amphotericin B (0.15%)** is preferred. * **Clinical Sign:** Fungal ulcers are characterized by **feathery margins**, **satellite lesions**, and a **dry, immune ring (Wessely ring)**. * **Cycloplegic of choice:** Atropine is preferred over Tropicamide due to its long duration of action and potent cycloplegic effect.

Q: What is the mechanism of action of beta-blockers in the management of glaucoma?

Decreased aqueous production. **Explanation:** **Mechanism of Action:** Beta-blockers (e.g., Timolol, Betaxolol) are a mainstay in glaucoma therapy. Their primary mechanism is the **reduction of aqueous humor production** by the ciliary body. Specifically, they block $\beta_2$-receptors located on the non-pigmented ciliary epithelium. This inhibition leads to a decrease in cyclic AMP (cAMP) levels, which reduces the active secretion of aqueous humor into the posterior chamber. **Analysis of Options:** * **Option A & C (Incorrect):** These describe the mechanism of **miotics** (like Pilocarpine) or **prostaglandin analogues** (like Latanoprost). Miotics cause contraction of the ciliary muscle, which pulls on the scleral spur to open the trabecular meshwork (increasing outflow). Prostaglandins primarily increase uveoscleral outflow. Beta-blockers have no significant effect on the drainage pathways. * **Option D (Incorrect):** Since beta-blockers only affect production and not outflow, "All of the above" is incorrect. **High-Yield Clinical Pearls for NEET-PG:** * **Timolol:** The "Gold Standard" non-selective beta-blocker. It is contraindicated in patients with **Asthma/COPD** (due to $\beta_2$ blockade causing bronchospasm) and **Bradycardia/Heart block** (due to $\beta_1$ blockade). * **Betaxolol:** A **cardioselective ($\beta_1$)** blocker. It is safer for patients with respiratory issues but is slightly less efficacious in lowering Intraocular Pressure (IOP) compared to Timolol. * **Levobunolol:** Longest acting topical beta-blocker. * **Side Effects:** Can cause "masked hypoglycemia" in diabetic patients and may worsen depression or impotence.

Q: Iris cysts are prevented by which medication?

Phenylephrine. **Explanation:** The correct answer is **Phenylephrine**. **Mechanism and Rationale:** Iris cysts (specifically miotic-induced cysts) are a known side effect of long-term use of potent, long-acting cholinesterase inhibitors (miotics) like **Echothiophate**. These cysts form at the pupillary margin due to the proliferation of the iris pigment epithelium. The underlying medical concept is that **Phenylephrine (2.5%)**, a sympathomimetic alpha-1 agonist, acts as a competitive stabilizer. When used concurrently with miotics, it prevents the hypertrophy and cystic changes of the pigment epithelium without neutralizing the pressure-lowering effect of the miotic. **Analysis of Incorrect Options:** * **Atropine (A):** This is a potent parasympatholytic (mydriatic-cycloplegic). While it dilates the pupil, it is not used to prevent cysts caused by miotics; in fact, its clinical action is the polar opposite of the drugs that cause the cysts. * **Pilocarpine (B):** This is a direct-acting miotic. While it can occasionally cause iris cysts, they are much more common with long-acting indirect miotics. It does not prevent them. * **Echothiophate (D):** This is an irreversible cholinesterase inhibitor and is the **primary cause** of these iris cysts, not the preventive agent. **Clinical Pearls for NEET-PG:** * **Echothiophate** is the most common culprit for iris cysts in children being treated for accommodative esotropia. * **Phenylephrine 2.5%** is the specific concentration used to prevent these cysts. * **Other side effects of Echothiophate:** Retinal detachment, cataract formation (anterior subcapsular), and prolonged apnea if succinylcholine is administered during anesthesia (due to depleted plasma pseudocholinesterase).

Q: Which medication is known to induce iris cyst formation?

Pilocarpine. **Explanation:** **Pilocarpine** is a direct-acting parasympathomimetic (miotic) that acts on the muscarinic receptors of the iris sphincter muscle. A well-documented side effect of long-term or high-dose miotic therapy, particularly with potent agents like Pilocarpine or Echothiophate, is the formation of **iris pigment epithelial cysts**. These cysts typically occur at the pupillary margin and are caused by the continuous, intense contraction of the iris muscles, which leads to the proliferation and cystic entrapment of the pigment epithelium. In children, these cysts can become large enough to obstruct the visual axis. **Analysis of Incorrect Options:** * **Atropine:** This is a parasympatholytic (mydriatic/cycloplegic). It causes pupillary dilation and paralysis of accommodation, rather than the pupillary constriction associated with cyst formation. * **Latanoprost:** A Prostaglandin analogue used in glaucoma. Its characteristic iris-related side effect is **increased iris pigmentation** (heterochromia) due to increased melanin synthesis, not cyst formation. * **Timolol:** A topical Beta-blocker that reduces aqueous humor production. It has no significant effect on the iris musculature or the pigment epithelium. **High-Yield Clinical Pearls for NEET-PG:** * **Prevention:** Iris cysts induced by miotics can often be prevented or minimized by the concurrent administration of **Phenylephrine 2.5%**. * **Other Pilocarpine Side Effects:** Retinal detachment (due to ciliary body contraction pulling the retina), brow ache (ciliary spasm), and miosis-induced night blindness. * **Drug of Choice:** Pilocarpine remains the drug of choice for **Acute Angle Closure Glaucoma** (once IOP is lowered) to pull the iris away from the angle.

Q: Ranibizumab is a monoclonal antibody against which of the following targets?

VEGF. **Explanation:** **Ranibizumab** is a recombinant humanized monoclonal antibody fragment (Fab) designed to bind and inhibit **Vascular Endothelial Growth Factor A (VEGF-A)**. VEGF is a potent cytokine that promotes angiogenesis (new blood vessel formation) and increases vascular permeability. In ophthalmology, excessive VEGF levels lead to pathological neovascularization and macular edema. By neutralizing VEGF, Ranibizumab prevents the growth of abnormal vessels and reduces leakage, making it a cornerstone in treating **Wet Age-related Macular Degeneration (AMD)**, Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO). **Analysis of Incorrect Options:** * **A. IL-6:** Interleukin-6 is a pro-inflammatory cytokine. Inhibitors like **Tocilizumab** are used in Rheumatoid Arthritis and Giant Cell Arteritis, but not as primary anti-angiogenic agents in the eye. * **B. CD-20:** This is a surface antigen on B-cells. **Rituximab** is the monoclonal antibody targeting CD-20, used in lymphomas and certain autoimmune conditions (e.g., Ocular Cicatricial Pemphigoid). * **D. EGFR:** Epidermal Growth Factor Receptor inhibitors like **Cetuximab** are used in treating systemic malignancies (e.g., colorectal cancer), not retinal vascular diseases. **High-Yield Clinical Pearls for NEET-PG:** * **Ranibizumab vs. Bevacizumab:** Ranibizumab is a Fab fragment (smaller molecule), whereas Bevacizumab is a full-length antibody. * **Aflibercept:** Another common agent, acts as a "VEGF Trap" by binding to VEGF-A, VEGF-B, and Placental Growth Factor (PlGF). * **Route of Administration:** These drugs are administered via **intravitreal injection** to ensure high local concentration and minimal systemic side effects. * **Common Indication:** The most frequent "high-yield" indication tested is **Exudative (Wet) AMD**.

Q: Which of the following medications causes lid retraction?

Apraclonidine. **Explanation:** **Correct Answer: D. Apraclonidine** **Mechanism of Action:** Apraclonidine is a potent **alpha-1 and alpha-2 adrenergic agonist**. Lid retraction occurs due to its stimulatory effect on the **Müller’s muscle**, which is a smooth muscle in the upper eyelid innervated by the sympathetic nervous system. When alpha-1 receptors are stimulated, the muscle contracts, leading to an elevation of the upper eyelid (widening of the palpebral fissure). **Clinical Utility:** This side effect is utilized diagnostically in the **Apraclonidine Test for Horner’s Syndrome**. In a normal eye, it has minimal effect, but in Horner’s (due to denervation supersensitivity), it causes significant lid elevation, helping confirm the diagnosis. **Why other options are incorrect:** * **A & B (Bimatoprost and Latanoprost):** These are Prostaglandin Analogues (PGAs). A classic side effect of PGAs is **Prostaglandin-associated Periorbitopathy (PAP)**, which causes deepening of the upper eyelid sulcus and **ptosis** (drooping), rather than retraction. They also cause eyelash growth and iris hyperpigmentation. * **C (Brimonidine):** While also an alpha-agonist, Brimonidine is highly selective for **alpha-2 receptors**. It lacks the significant alpha-1 activity required to stimulate Müller’s muscle; therefore, it does not typically cause lid retraction. **High-Yield Clinical Pearls for NEET-PG:** * **Apraclonidine:** Primarily used to prevent post-laser (YAG capsulotomy/Iridotomy) IOP spikes. * **Tachyphylaxis:** Long-term use of Apraclonidine is limited by a high incidence of follicular conjunctivitis and loss of efficacy (tachyphylaxis). * **Mnemonic:** **A**praclonidine **A**scends the lid (Retraction); **P**rostaglandins **P**recipitate the lid (Ptosis).

Question 1

Which of the following medications is contraindicated in patients with allergy to sulfonamides?

Accepted Answer

Brinzolamide

Answer

Levobunolol

Answer

Bimatoprost

Answer

Brimonidine

Question 2

What is the maximum safe dose of lignocaine with adrenaline for local blocks in ophthalmic surgeries?

Accepted Answer

7 mg/kg

Answer

3 mg/kg

Answer

5 mg/kg

Answer

10 mg/kg

Question 3

Which of the following is used as an adjuvant therapy for fungal corneal ulcer?

Accepted Answer

Atropine eye drops

Answer

Pilocarpine eye drops

Answer

Dexamethasone

Answer

Lidocaine

Question 4

Which of the following vitamins is used in the treatment of optic neuritis?

Accepted Answer

Vitamin C

Answer

Vitamin A

Answer

Vitamin B

Answer

Vitamin D

Question 5

What is the mechanism of action of beta-blockers in the management of glaucoma?

Accepted Answer

Decreased aqueous production

Answer

Increased aqueous outflow

Answer

Opening of the trabecular meshwork

Answer

All of the above

Question 6

All of the following drugs are used in the management of acute anterior uveitis except?

Accepted Answer

Pilocarpine

Answer

Atropine

Answer

Timolol

Answer

Propranolol

Question 7

Iris cysts are prevented by which medication?

Accepted Answer

Phenylephrine

Answer

Atropine

Answer

Pilocarpine

Answer

Ecothiopate

Question 8

Which medication is known to induce iris cyst formation?

Accepted Answer

Pilocarpine

Answer

Atropine

Answer

Latanoprost

Answer

Timolol

Question 9

Ranibizumab is a monoclonal antibody against which of the following targets?

Accepted Answer

VEGF

Answer

IL-6

Answer

CD-20

Answer

EGFR

Question 10

Which of the following medications causes lid retraction?

Accepted Answer

Apraclonidine

Answer

Bimatoprost

Answer

Latanoprost

Answer

Brimonidine

Ophthalmic Pharmacology — MCQs

Ophthalmic Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?